INDSWFTLAB.NS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 11:59):

Stats
Dagens volum	522 878
Gjennomsnittsvolum	995 132
Markedsverdi	7.21B
EPS	INR0 ( 2024-02-12 )
Neste inntjeningsdato	( INR0 ) 2024-05-27
Last Dividend	INR1.000 ( 2011-09-20 )
Next Dividend	INR0 ( N/A )
P/E	16.59
ATR14	INR0.215 (0.18%)

Volum Korrelasjon

Lang: 0.11 (neutral)

Kort: 0.39 (neutral)

Signal:(40.749) Neutral

Ind-Swift Laboratories Korrelasjon

10 Mest positive korrelasjoner
PVP.NS	0.827
ICICIPHARM.NS	0.813
KIMS.NS	0.811

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Ind-Swift Laboratories Korrelasjon - Valuta/Råvare

0.32
( neutral )

0.30
( neutral )

0.00
( neutral )

-0.01
( neutral )

-0.84
( strong negative )

0.29
( neutral )

Ind-Swift Laboratories Økonomi

Annual	2022
Omsetning:	INR12.07B
Bruttogevinst:	INR5.52B (45.70 %)
EPS:	INR8.06

FY	2022
Omsetning:	INR12.07B
Bruttogevinst:	INR5.52B (45.70 %)
EPS:	INR8.06

FY	2022
Omsetning:	INR10.39B
Bruttogevinst:	INR4.28B (41.20 %)
EPS:	INR-0.360

FY	2021
Omsetning:	INR8.91B
Bruttogevinst:	INR3.61B (40.51 %)
EPS:	INR-0.530

Financial Reports:

No articles found.

Ind-Swift Laboratories Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Ind-Swift Laboratories Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 1.760 - low (50.00%) | Divividend Growth Potential Score: 3.48 - No dividend growth expected in the near future

Information

First Dividend	INR1.000	2004-09-23
Last Dividend	INR1.000	2011-09-20
Next Dividend	INR0	N/A
Payout Date	2011-10-26
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	INR9.00	--
Avg. Dividend % Per Year	0.00%	--
Score	1.37	--
Div. Sustainability Score	1.760
Div.Growth Potential Score	3.48
Div. Directional Score	2.62	--

Next Divdend (Est)
(2024-06-27)

INR0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

1.37

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR0	0.00%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SARDAEN.NS	Dividend Junior	2023-09-07	Annually	15	0.65%
MAGADSUGAR.NS	Dividend Junior	2023-07-13	Annually	7	1.78%
GMDCLTD.NS	Dividend Knight	2023-09-22	Annually	23	3.41%
ASTRAMICRO.NS	Dividend Junior	2023-08-23	Annually	20	0.49%
TITAN.NS	Dividend Junior	2023-07-13	Annually	20	0.35%
PETRONET.NS	Dividend Knight	2023-08-18	Semi-Annually	18	2.36%
JASH.NS	Dividend Junior	2023-09-22	Annually	7	0.57%
DBOL.NS	Dividend Junior	2023-06-23	Insufficient data to determine frequency	2	0.56%
SILINV.NS	Dividend Junior	2023-08-18	Annually	23	0.63%
MBAPL.NS	Dividend Junior	2023-09-18	Annually	8	0.44%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0362	1.500	9.28	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.0612	1.500	-0.431	-0.647	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	2.56	1.000	-0.163	-0.163	[3 - 30]
operatingCashFlowPerShareTTM	16.90	2.00	4.37	8.74	[0 - 30]
freeCashFlowPerShareTTM	16.90	2.00	1.552	3.10	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.476	1.000	5.40	5.40	[0.2 - 0.8]
operatingProfitMarginTTM	0.181	1.000	8.37	8.37	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				1.760

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	17.00	1.000	8.38	0	[1 - 100]
returnOnEquityTTM	0.0612	2.50	-0.277	-0.647	[0.1 - 1.5]
freeCashFlowPerShareTTM	16.90	2.00	4.37	3.10	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	16.90	2.00	4.37	8.74	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.530	1.500	9.80	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0838	1.000	-0.406	0	[0.1 - 0.5]
Total Score				3.48

Ind-Swift Laboratories

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.